Evidence of innate lymphoid cell redundancy in humans

Vély, Frederic; Barlogis, Vincent; Vallentin, Blandine; Neven, Bénédicte; Pipéroglou, Christelle; Ebbo, Mikaël; Perchet, Thibaut; Petit, Maxime; Yessaad, Nadia; Touzot, Fabien; Bruneau, Julie; Mahlaoui, Nizar; Zucchini, Nicolas; Farnarier, Catherine; Gautier, Michel; Moshous, Despina; Blanche, Stéphane; Dujardin, Arnaud; Spits, Hergen; Distler, Jörg H W; Ramming, Andreas; Pïcard, Capucine; Golub, Rachel; Fischer, Alain; Vivier, Éric

doi:10.1038/ni.3553

Cited by 267 publications

(201 citation statements)

References 50 publications

Supporting

Mentioning

183

Contrasting

Unclassified

Order By: Relevance

“…Interestingly, the impaired recovery of ILCs after stem cell transplantation was much greater in patients receiving non-myeloablative conditioning therapy. The impaired recovery of ILCs after transplant was not associated with an increased risk of infectious diseases, suggesting that ILCs may not be critical in the presence of T and B cells for the control of infectious pathogens (33). Our findings suggest that ILCs may only be critical in specific uncommon settings, such as assisting in the control of the persistent inflammation in the GI tract during severe aGVHD.…”

Section: 2mentioning

confidence: 70%

Type 2 innate lymphoid cells treat and prevent acute gastrointestinal graft-versus-host disease

Bruce¹,

Stefanski²,

Vincent³

et al. 2017

Journal of Clinical Investigation

103

View full text Add to dashboard Cite

Section: 2mentioning

confidence: 70%

Type 2 innate lymphoid cells treat and prevent acute gastrointestinal graft-versus-host disease

Bruce¹,

Stefanski²,

Vincent³

et al. 2017

Journal of Clinical Investigation

103

View full text Add to dashboard Cite

“…Redundancy of ILCs was observed in patients with severe combined immunodeficiency (SCID) who received allogeneic bone marrow transplants. These individuals show successful T and B cell reconstitution, but not ILC reconstitution, yet they do not have increased susceptibility to any particular infections, even after nearly 40 years 89 , suggesting that ILCs are dispensable for protection against infection in humans.…”

Section: Intestinal Iel Functionsmentioning

confidence: 97%

Diverse developmental pathways of intestinal intraepithelial lymphocytes

2018

View full text Add to dashboard Cite

The intestinal epithelial barrier is patrolled by resident intraepithelial lymphocytes (IELs) that are involved in host defence against pathogens, wound repair and homeostatic interactions with the epithelium, microbiota and nutrients. Intestinal IELs are one of the largest populations of lymphocytes in the body and comprise several distinct subsets, the identity and lineage relationships of which have long remained elusive. Here, we review advances in unravelling the complexity of intestinal IEL populations, which comprise conventional αβ T cell receptor (TCRαβ)+ subsets, unconventional TCRαβ+ and TCRγδ+ subsets, group 1 innate lymphoid cells (ILC1s) and ILC1-like cells. Although these intestinal IEL lineages have partially overlapping effector programmes and recognition properties, they have strikingly different developmental pathways. We suggest that evolutionary pressure has driven the recurrent generation of cytolytic effector lymphocytes to protect the intestinal epithelial layer, but they may also precipitate intestinal inflammatory disorders, such as coeliac disease.

show abstract

“…There are few reports on long-term NK cell reconstitution, and the consequences of inadequate NK cell reconstitution remain incompletely described 26,27 . The current recommendation is to monitor NK cell counts (CD3-/CD56+ &/or CD16+) plus/minus NK cell function after HCT.…”

Section: Immune Reconstitutionmentioning

confidence: 99%

Mini Review: Screening and Management of Late Effects in Patients with Severe Combined Immunodeficiency after Allogeneic Hematopoietic Cell Transplantation

Heimall¹

2018

J Pediatrics & Pediatr Med

View full text Add to dashboard Cite

Severe combined immunodeficiency (SCID) is a group of the most severe of primary immunodeficiencies and is typically fatal in the first year of life without hematopoietic cell transplantation (HCT). Improved transplantation techniques and supportive care measures have resulted in improved survival following HCT. Furthermore, patients are being diagnosed earlier since the widespread implementation of SCID newborn screening in the United States and moving on to transplantation before 3.5 months of age. As such, most SCID patients are now expected to live well into adulthood following successful HCT. Many centers are using conditioning with alkylating agents, including busulfan and melphalan, pre-transplantation to achieve full T and B cell immune reconstitution; however, significant concerns remain regarding the attendant risks of using chemotherapeutic agents in early infancy. Several long-term follow-up studies have demonstrated high rates of non-immunologic late effects depending on the conditioning regimen employed and SCID genotype. The full risk of conditioning in this patient population remains incompletely characterized, and further research on post-HCT outcomes is needed. It is imperative that all providers caring for SCID survivors both in childhood and adulthood be aware of the risk of late effects. Guidelines for long-term follow-up were recently published, and the recommendations are briefly summarized here.

show abstract

Evidence of innate lymphoid cell redundancy in humans

Cited by 267 publications

References 50 publications

Type 2 innate lymphoid cells treat and prevent acute gastrointestinal graft-versus-host disease

Type 2 innate lymphoid cells treat and prevent acute gastrointestinal graft-versus-host disease

Diverse developmental pathways of intestinal intraepithelial lymphocytes

Mini Review: Screening and Management of Late Effects in Patients with Severe Combined Immunodeficiency after Allogeneic Hematopoietic Cell Transplantation

Contact Info

Product

Resources

About